ATLASATLAS fair value
ATLAS has no fair value for this stock today.
Black Diamond Therapeutics (BDTX)
Black Diamond Therapeutics stock price today, ATLAS forecast and fair value
Healthcare · Biotechnology · NASDAQ
$1.75▲ +3.55%
Prices as of Oct 27, 2026 · USD
Chance of rising in 1 month
46%
that it ends higher than today in 21 sessions
0%coin flip 50%100%
This is just the summary. See everything on Black Diamond Therapeutics in ATLAS
ATLAS's own quantitative analysis, all in one place.
- Simulation and expected rangeThousands of simulated scenarios: how far the price could rise or fall.
- Officers and shareholdersWho runs the company and which funds hold its shares.
- Customer and supplier mapWho it does business with, from its own filings.
- ATLAS builds your portfolioAnswer a short test and get portfolios that fit you.
- AlertsWe let you know when something changes in your stocks.
See everything included
- Valuation and financialsFair value step by step, quarterly accounts and upcoming events.
- NewsThe latest on the company, in one place.
- Crisis simulatorHow your portfolio would do in a crash like 2008.
- Practice risk-free$10,000 in virtual money to invest at real prices.
- Global screenerSearch US stocks and stocks from 47 countries with filters.
On Black Diamond Therapeutics
- Simulation and expected rangeThousands of simulated scenarios: how far the price could rise or fall.
- Officers and shareholdersWho runs the company and which funds hold its shares.
- Customer and supplier mapWho it does business with, from its own filings.
- Valuation and financialsFair value step by step, quarterly accounts and upcoming events.
- NewsThe latest on the company, in one place.
And for you
- ATLAS builds your portfolioAnswer a short test and get portfolios that fit you.
- AlertsWe let you know when something changes in your stocks.
- Crisis simulatorHow your portfolio would do in a crash like 2008.
- Practice risk-free$10,000 in virtual money to invest at real prices.
- Global screenerSearch US stocks and stocks from 47 countries with filters.
Plans from €3.99 a month.
ATLAS's model gives Black Diamond Therapeutics a 46% chance of finishing higher a month from now (21 trading sessions) than today: close to a coin flip.
In half of the simulated outcomes the price ends between $1.48 and $1.97; in 9 out of 10, between $1.15 and $2.54. Estimated annual volatility is 84%.
Price, last 12 months (weekly close)
Key numbers
- Market cap
- $109M
- 52-week high
- $4.94
- 52-week low
- $1.60
- Revenue (12 months)
- $70.0M
- Gross margin
- 0.0%
- Operating margin
- 28.4%
- Net margin
- 32.0%
- Return on equity
- -37.2%
- Free cash flow (12 months)
- $-23.6M
- Beta
- 3.31
What this means
ATLAS does not publish a fair value for BDTX right now, but it does show its odds of rising: close to a coin flip.
Over the last 52 weeks BDTX has traded between $1.60 and $4.94. Today it is 64.6% below that high and 9% above its low.
Its beta is 3.31: it tends to move more than the market, both up and down.
About the company
Black Diamond Therapeutics, Inc. is a clinical-stage oncology company focused on developing precision medicines for genetically defined cancers.
Want to see everything about Black Diamond Therapeutics?
Get started →Plans from €3.99 a month.
Comparable companies
Other companies in the same line of business:
Frequently asked questions
What does Black Diamond Therapeutics do?
Black Diamond Therapeutics, Inc. is a clinical-stage oncology company focused on developing precision medicines for genetically defined cancers.
What is the chance BDTX goes up next month?
46%: close to a coin flip. In half of the simulated outcomes, BDTX ends the month between $1.48 and $1.97.
How big is Black Diamond Therapeutics and what is its P/E ratio?
Black Diamond Therapeutics's market capitalization is $109M. We do not show a P/E because it has no positive earnings to base one on.
How volatile is BDTX?
ATLAS estimates annual volatility at 84%. In a typical month, half of the outcomes end between $1.48 and $1.97.
Not investment advice. ATLAS estimates are produced by statistical models from public data; they can be wrong and past performance does not predict future results. Consider your own situation before investing. Disclaimer